




# Is biopsy the next step?

## Find out with Prostate Health Index from ARUP Laboratories.

Prostate Health Index (PHI) is a safe, less-invasive step in the process of diagnosing prostate cancer. It's a simple, FDA-approved blood test that uses an algorithm to assess total PSA, free PSA, and p2PSA.

Using PHI as part of a multivariable diagnostic process can significantly reduce the number of unnecessary biopsies.

**Be confident in your diagnostic decisions about prostate cancer.**



## Prostate Health Index (PHI)

	PROSTATE HEALTH INDEX (3000134)	4KSCORE (2014059)
Ordering recommendation	<ul style="list-style-type: none"><li>Individuals aged 50 or older</li><li>Total PSA between 4 and 10 ng/mL</li><li>DRE not suspicious for cancer (specimens for testing should be drawn before DRE or other prostate manipulations)</li></ul>	<ul style="list-style-type: none"><li>Individuals aged 45-80</li><li>No DRE in previous 4 days</li><li>No previous prostate cancer diagnosis</li><li>No treatment of BPH, invasive urologic procedure with secondary PSA evaluation, or 5-ARI therapy in past 6 months</li></ul>
Specimen type	1.5 mL serum (critical frozen)	4 mL serum (refrigerated or frozen)
Testing location	In-house at ARUP, under standardized conditions in a CLIA- and CAP-certified lab	Sendout
Turnaround time	Results within 1-7 days (average 4-6 days)	3-6 days
FDA approval	YES	YES

For pricing information, please contact your ARUP Account Executive.

BPH, benign prostatic hyperplasia; DRE, digital rectal examination; PSA, prostate-specific antigen

For more information about prostate cancer screening, visit  
[arupconsult.com/content/prostate-cancer](https://arupconsult.com/content/prostate-cancer).



*A nonprofit enterprise of the University of Utah  
and its Department of Pathology*

[aruplab.com/PHI-1](https://aruplab.com/PHI-1)

